Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

ddgcabd Jan. 6 at 7:05 PM

$IMNN Constipated citizen finally took the coward's way out. Lying POS scumbag.

0 · Reply

RaKa82 Jan. 6 at 6:07 PM

$IMNN https://www.pharmavoice.com/news/imunon-ovarian-cancer-dna-biotech/804657/

0 · Reply

RaKa82 Jan. 6 at 5:02 PM

$IMNN $840M for a PRE-CLINCAL oncology asset. How much for a de-risked PHASE 3 oncology asset that is poised to obliterate the prior standard of care in 1L hard to treat oncology indication?? Just asking for a friend … https://share.google/ocxiCJvXuXl86CN6x

0 · Reply

MrEd916 Jan. 6 at 2:20 PM

$IMNN double top or break through? Would like to see it how old above 4.05.

0 · Reply

RaKa82 Jan. 6 at 2:33 AM

$IMNN they’ll be at JPM next week. Question is what will come out of it …

1 · Reply

MrEd916 Jan. 5 at 9:08 PM

$IMNN could not stay above the 50 day. Have we hit the ceiling???

1 · Reply

ConcernedCitizen23 Jan. 5 at 6:00 PM

$IMNN can you imagine once a hedge fund manager finds out a family member is living longer because of a new medication from a micro cap what can happen?!? Can’t wait for the new phase 3 sites to be announced!

0 · Reply

Shrekislove69 Jan. 5 at 4:11 PM

$IMNN just need this to go to 50$ and my 2026 will be made haha

0 · Reply

RaKa82 Jan. 5 at 3:13 PM

$IMNN something brewing here, or random climb the last few days?

1 · Reply

MrEd916 Jan. 5 at 3:12 PM

$IMNN looking for any pull back to accumulate more.

1 · Reply

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

Dec 29, 2025, 11:10 AM EST - 8 days ago

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

Nov 13, 2025, 5:31 PM EST - 7 weeks ago

Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:45 AM EST - 7 weeks ago

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 5:11 PM EST - 2 months ago

Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript

Nov 10, 2025, 1:30 PM EST - 2 months ago

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

Nov 10, 2025, 7:30 AM EST - 2 months ago

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

Nov 7, 2025, 8:05 AM EST - 2 months ago

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

Nov 6, 2025, 8:05 AM EST - 2 months ago

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Nov 4, 2025, 8:05 AM EST - 2 months ago

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 30, 2025, 8:00 AM EDT - 2 months ago

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

Oct 23, 2025, 10:01 AM EDT - 2 months ago

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

Oct 20, 2025, 8:05 AM EDT - 2 months ago

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 17, 2025, 8:10 AM EDT - 2 months ago

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

Oct 14, 2025, 8:20 AM EDT - 3 months ago

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

Sep 22, 2025, 8:05 AM EDT - 3 months ago

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Sep 19, 2025, 8:05 AM EDT - 3 months ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

Aug 28, 2025, 8:05 AM EDT - 4 months ago

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Aug 5, 2025, 4:00 PM EDT - 5 months ago

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 1:26 PM EDT - 5 months ago

Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 5 months ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:05 AM EDT - 5 months ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 5 months ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

Jul 28, 2025, 8:05 AM EDT - 5 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 23, 2025, 8:00 AM EDT - 5 months ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 6 months ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 7 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 7 months ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 3, 2025, 8:05 AM EDT - 7 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 7 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 27, 2025, 8:05 AM EDT - 8 months ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 8 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 8 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 15, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 12, 2025, 12:56 PM EDT - 8 months ago

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

May 12, 2025, 8:00 AM EDT - 8 months ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 8 months ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 9 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 10 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 2:32 PM EST - 11 months ago

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 8:05 AM EST - 11 months ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 11 months ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 11 months ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 19, 2025, 8:05 AM EST - 11 months ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 10, 2025, 8:05 AM EST - 11 months ago

IMUNON Appoints Douglas V. Faller, M.D.

Dec 19, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Dec 10, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

ddgcabd Jan. 6 at 7:05 PM

$IMNN Constipated citizen finally took the coward's way out. Lying POS scumbag.

0 · Reply

RaKa82 Jan. 6 at 6:07 PM

$IMNN https://www.pharmavoice.com/news/imunon-ovarian-cancer-dna-biotech/804657/

0 · Reply

RaKa82 Jan. 6 at 5:02 PM

0 · Reply

MrEd916 Jan. 6 at 2:20 PM

$IMNN double top or break through? Would like to see it how old above 4.05.

0 · Reply

RaKa82 Jan. 6 at 2:33 AM

$IMNN they’ll be at JPM next week. Question is what will come out of it …

1 · Reply

MrEd916 Jan. 5 at 9:08 PM

$IMNN could not stay above the 50 day. Have we hit the ceiling???

1 · Reply

ConcernedCitizen23 Jan. 5 at 6:00 PM

0 · Reply

Shrekislove69 Jan. 5 at 4:11 PM

$IMNN just need this to go to 50$ and my 2026 will be made haha

0 · Reply

RaKa82 Jan. 5 at 3:13 PM

$IMNN something brewing here, or random climb the last few days?

1 · Reply

MrEd916 Jan. 5 at 3:12 PM

$IMNN looking for any pull back to accumulate more.

1 · Reply

Shrekislove69 Jan. 5 at 1:45 PM

$IMNN bullish

0 · Reply

ddgcabd Jan. 4 at 9:34 PM

$IMNN Also based on what the CEO said, their p2 trial design was deliberately stacked with responders, which upon correction, comfortably predicts p3 failure

0 · Reply

ArcaneFoxx Jan. 4 at 4:25 AM

$IMNN

0 · Reply

ConcernedCitizen23 Jan. 2 at 4:41 PM

$IMNN based on what the ceo said at the Harvard club in November the next development is expanding phase 3 sites

0 · Reply

MrEd916 Jan. 2 at 4:23 PM

$IMNN next stop the 50 day at 4.03. either it clears it or hits the ceiling.

0 · Reply

rrch Jan. 2 at 3:44 PM

$IMNN I am looking for a partner announcement at the j. P. Morgan health care conference next week there is a building positive vibe about there science

3 · Reply

MrEd916 Jan. 2 at 12:58 PM

$IMNN Despite the heavier than average volume and the recent 25% climb, still feels like the stock is under the radar.

2 · Reply

ConcernedCitizen23 Dec. 31 at 7:31 PM

$IMNN I encourage everyone to view the scientific update video from the Harvard Club last month. The ceo mentioned doubling the phase 3 sites from 4 to 8. The new sites could be the phase 2 sites including Johns Hopkins, Sloan Kettering in New York and MD Anderson. Can’t wait to see what happens after that announcement!

1 · Reply

deedeethegenius Dec. 31 at 7:30 PM

$IMNN what is this

1 · Reply

MrEd916 Dec. 31 at 7:08 PM

$IMNN Now if we can just get on seeking alphas biggest gainers list.

0 · Reply

JohnTrack Dec. 31 at 3:34 PM

$IMNN waiting for a real move!!

0 · Reply

ConcernedCitizen23 Dec. 31 at 1:26 PM

$IMNN now that they have enough money for at least 6 months…I wonder if expanding phase 3 is next ?!?

3 · Reply

Market Cap	12.13M
Revenue (ttm)	0.00
Net Income (ttm)	-18.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	60,209
Avg Vol	58,780
Day's Range	N/A - N/A
Shares Out	3.07M
Stochastic %K	79%
Beta	1.94
Analysts	Strong Sell
Price Target	$25.09